<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00074581</url>
  </required_header>
  <id_info>
    <org_study_id>HPTN 052</org_study_id>
    <secondary_id>10068</secondary_id>
    <nct_id>NCT00074581</nct_id>
  </id_info>
  <brief_title>Preventing Sexual Transmission of HIV With Anti-HIV Drugs</brief_title>
  <official_title>A Randomized Trial to Evaluate the Effectiveness of Antiretroviral Therapy Plus HIV Primary Care Versus HIV Primary Care Alone to Prevent the Sexual Transmission of HIV-1 in Serodiscordant Couples</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>HIV Prevention Trials Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      This study will determine whether anti-HIV drugs can prevent the sexual transmission of HIV
      among couples in which one partner is HIV infected and the other is not.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Initiation of antiretroviral therapy (ART) in the HIV infected population has been shown to
      dramatically reduce the morbidity and mortality of HIV infection through sustained reduction
      in HIV viral replication. However, such therapy does not cure HIV infection or prevent the
      spread of the virus. ART may, however, make HIV infected people less contagious by lowering
      plasma HIV-1 RNA levels, compared with people not on ART. This study seeks to determine
      whether initiating ART in ART-naive, HIV infected people can prevent the sexual transmission
      of HIV among HIV-discordant couples, as well as to demonstrate whether quality of life
      changes with the initiation of ART. Both opposite and same sex couples will be recruited at
      study sites in Brazil, India, Malawi, Thailand, the United States, and Zimbabwe for this
      study.

      Participating couples will be enrolled for approximately 78 months (6.5 years). Couples will
      be randomly assigned to one of two arms. HIV infected partners in Arm 1 will begin ART in
      addition to receiving HIV primary care. HIV infected partners in Arm 2 will receive HIV
      primary care. When the CD4 count in these participants reaches 200 to 250 cells/mm3, drops
      below 200 cells/mm3, or develops an AIDS-defining illness, they will initiate ART. All
      couples will receive HIV counseling and have their urine and blood collected at screening and
      enrollment, and at selected monthly, quarterly, and yearly intervals. They will be asked to
      periodically report information about their adherence to the ART regimen.

      Note: Per LoA#5, on the Data and Safety and Monitoring Board (DSMB) recommendation, as of May
      10, 2011, all HIV-infected participants in Arm 2 who have not already initiated ART will be
      offered ART as soon as possible.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2005</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Linked Partner HIV Infection Rates in Early-ART and Delayed-ART Arms</measure>
    <time_frame>Throughout study</time_frame>
    <description>incident HIV infections occurring in the partners (HIV-negative at enrollment) of randomized HIV-infected index (HIV-positive at enrollment) cases are assessed, by arm. Only acquisition from the index partner were included in the primary analysis, therefore, each endpoint was required to be confirmed (by genotyping) such that the viral envelop sequence in the index case matched that of the partner.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>All Partner HIV Infection Rates in Early-ART and Delayed-ART Arms</measure>
    <time_frame>Throughout study</time_frame>
    <description>All Incident HIV infections occurring in the partners (HIV-negative at enrollment) of randomized HIV-infected index (HIV-positive at enrollment) cases are assessed, by arm.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">3526</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will begin ART in addition to receiving HIV primary care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive HIV primary care. When the CD4 count in these participants reaches 200 to 250 cells/mm3, drops below 200 cells/mm3, or develops an AIDS-defining illness, they will initiate ART.
Note: Per LoA#5, on the Data and Safety and Monitoring Board (DSMB) recommendation, as of May 10, 2011, all HIV-infected participants in Arm 2 who have not already initiated ART will be offered ART as soon as possible.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atazanavir</intervention_name>
    <description>300 mg taken orally once daily</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>Reyataz</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Didanosine</intervention_name>
    <description>400 mg taken orally once daily</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>Videx</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Efavirenz</intervention_name>
    <description>600 mg taken orally once daily</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>Sustiva</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Emtricitabine/Tenofovir disoproxil fumarate</intervention_name>
    <description>200 mg emtricitabine/ 300 mg tenofovir disoproxil fumarate tablet taken orally once daily</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>Truvada</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lamivudine</intervention_name>
    <description>300 mg taken orally once daily</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>Epivir</other_name>
    <other_name>3TC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lopinavir/Ritonavir</intervention_name>
    <description>200 mg lopinavir/ 50 mg ritonavir tablet taken orally once daily</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>Kaletra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nevirapine</intervention_name>
    <description>200 mg taken orally once daily for 14 days followed by 200 mg taken orally twice daily</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>Viramune</other_name>
    <other_name>NVP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Stavudine</intervention_name>
    <description>Dosage depends on weight</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>Zerit</other_name>
    <other_name>d4T</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir disoproxil fumarate</intervention_name>
    <description>300 mg taken orally once daily</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>Viread</other_name>
    <other_name>TDF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zidovudine/Lamivudine</intervention_name>
    <description>150 mg lamivudine/ 300 mg zidovudine tablet taken orally twice daily</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>Combivir</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for HIV Infected Partner:

          -  Positive HIV test within 60 days of study entry

          -  CD4 count between 350 and 550 cells/mm3 within 30 days of study entry

          -  If pregnant or breastfeeding, willing to be randomized to either arm of the study

        Inclusion Criteria for HIV Uninfected Partner:

          -  Negative HIV test within 14 days of study entry

        Inclusion Criteria for Both Partners:

          -  Plans to maintain sexual relationship with partner

          -  Reports having sex (vaginal or anal) with partner at least three times in the last 3
             months

          -  Willing to disclose HIV test results to partner

          -  Plans to stay in the area and does not have a job or other obligations that may
             require long absences during the duration of the study

        Exclusion Criteria for HIV Infected Partner:

          -  Current or previous use of any ART. Participants who previously took a short-term
             course of ART for prevention of mother-to-child transmission of HIV are not excluded.

          -  Documented or suspected acute hepatitis within 30 days of study entry, if the infected
             partner's starting regimen in the study contains nevirapine or atazanavir

          -  Current or previous AIDS-defining illness or opportunistic infection

          -  Documented or suspected acute hepatitis within 30 days prior to study entry

          -  Acute therapy of serious medical illnesses within 14 days prior to study entry

          -  Radiation therapy or systemic chemotherapy within 45 days prior to study entry

          -  Immunomodulatory or investigational therapy within 30 days prior to study entry

          -  Active drug or alcohol dependence that, in the opinion of the investigator, would
             interfere with the study

          -  Vomiting or inability to swallow medications

          -  Require certain medications

          -  Allergy or sensitivity to any of the study drugs

        Exclusion Criteria for Both Partners:

          -  History of injection drug use within 5 years of study entry

          -  Previous and/or current participation in an HIV vaccine study

          -  Currently detained in jail or for treatment of a psychiatric or physical illness

          -  Any condition that, in the opinion of the study staff, would make participation in the
             study unsafe, complicate interpretation of study outcome data, or otherwise interfere
             with achieving the study objectives

          -  Certain abnormal laboratory values
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Myron S. Cohen, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of North Carolina, Chapel Hill</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fenway Community Health Ctr. CRS</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gaborone CRS</name>
      <address>
        <city>Gaborone</city>
        <country>Botswana</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Geral de Nova Iguaçu CRS (HGNI CRS)</name>
      <address>
        <city>Nova Iguacu</city>
        <state>Rio de Janeiro</state>
        <zip>26030-380</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Nossa Senhora da Conceicao CRS</name>
      <address>
        <city>Port Alegre</city>
        <state>Rio Grande do Sul</state>
        <zip>91350 200</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HSE-Hospital dos Servidores do Estado CRS</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>20221-903</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de Pesquisa Clinica Evandro Chagas (IPEC) CRS</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>21040-360</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NARI Clinic at Gadikhana Dr. Kotnis Municipal Dispensary CRS</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411002</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NARI Clinic at NIV CRS</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411011</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NARI Pune CRS</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411026</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chennai Antiviral Research and Treatment (CART) CRS</name>
      <address>
        <city>Chennai</city>
        <state>Tamil Nadu</state>
        <zip>600113</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kisumu Crs</name>
      <address>
        <city>Kisumu</city>
        <state>Nyanza</state>
        <zip>40100</zip>
        <country>Kenya</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Blantyre CRS</name>
      <address>
        <city>Blantyre</city>
        <country>Malawi</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Malawi CRS</name>
      <address>
        <city>Lilongwe</city>
        <country>Malawi</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Soweto HPTN CRS</name>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <zip>2001</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wits Helen Joseph Hospital CRS (Wits HJH CRS)</name>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <zip>2092</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CMU HIV Prevention CRS</name>
      <address>
        <city>Chiang Mai</city>
        <zip>50202</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Parirenyatwa CRS</name>
      <address>
        <city>Harare</city>
        <country>Zimbabwe</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Botswana</country>
    <country>Brazil</country>
    <country>India</country>
    <country>Kenya</country>
    <country>Malawi</country>
    <country>South Africa</country>
    <country>Thailand</country>
    <country>United States</country>
    <country>Zimbabwe</country>
  </location_countries>
  <reference>
    <citation>Chan DJ. Fatal attraction: sex, sexually transmitted infections and HIV-1. Int J STD AIDS. 2006 Oct;17(10):643-51. Review.</citation>
    <PMID>17059632</PMID>
  </reference>
  <reference>
    <citation>Chan DJ. Factors affecting sexual transmission of HIV-1: current evidence and implications for prevention. Curr HIV Res. 2005 Jul;3(3):223-41. Review.</citation>
    <PMID>16022655</PMID>
  </reference>
  <reference>
    <citation>Davis CW, Doms RW. HIV transmission: closing all the doors. J Exp Med. 2004 Apr 19;199(8):1037-40. Epub 2004 Apr 12. Review.</citation>
    <PMID>15078894</PMID>
  </reference>
  <reference>
    <citation>Gupta K, Klasse PJ. How do viral and host factors modulate the sexual transmission of HIV? Can transmission be blocked? PLoS Med. 2006 Feb;3(2):e79. Epub 2006 Feb 28. Review.</citation>
    <PMID>16492075</PMID>
  </reference>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 16, 2003</study_first_submitted>
  <study_first_submitted_qc>December 16, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 17, 2003</study_first_posted>
  <results_first_submitted>September 9, 2016</results_first_submitted>
  <results_first_submitted_qc>September 9, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 31, 2016</results_first_posted>
  <last_update_submitted>November 3, 2016</last_update_submitted>
  <last_update_submitted_qc>November 3, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 7, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV Infections</keyword>
  <keyword>HIV Seronegativity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Lopinavir</mesh_term>
    <mesh_term>Atazanavir Sulfate</mesh_term>
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
    <mesh_term>Zidovudine</mesh_term>
    <mesh_term>Nevirapine</mesh_term>
    <mesh_term>Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
    <mesh_term>Stavudine</mesh_term>
    <mesh_term>Didanosine</mesh_term>
    <mesh_term>Efavirenz</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Early-ART</title>
          <description>Participants will begin ART in addition to receiving HIV primary care
Atazanavir: 300 mg taken orally once daily
Didanosine: 400 mg taken orally once daily
Efavirenz: 600 mg taken orally once daily
Emtricitabine/Tenofovir disoproxil fumarate: 200 mg emtricitabine/ 300 mg tenofovir disoproxil fumarate tablet taken orally once daily
Lamivudine: 300 mg taken orally once daily
Lopinavir/Ritonavir: 200 mg lopinavir/ 50 mg ritonavir tablet taken orally once daily
Nevirapine: 200 mg taken orally once daily for 14 days followed by 200 mg taken orally twice daily
Stavudine: Dosage depends on weight
Tenofovir disoproxil fumarate: 300 mg taken orally once daily
Zidovudine/Lamivudine: 150 mg lamivudine/ 300 mg zidovudine tablet taken orally twice daily
Note: Sites could also use locally supplied, FDA-approved drugs if they could be purchased with nonstudy funds. For participants with virologic failure, specified second-line treatment regimens were provided.</description>
        </group>
        <group group_id="P2">
          <title>Delayed-ART</title>
          <description>Participants will receive HIV primary care. When the CD4 count in these participants reaches 200 to 250 cells/mm3, drops below 200 cells/mm3, or develops an AIDS-defining illness, they will initiate ART.
(Same drug regimen as that described in the early-ART arm)
Note: Per LoA#5, on the Data and Safety and Monitoring Board (DSMB) recommendation, as of May 10, 2011, all HIV-infected participants in Arm 2 who have not already initiated ART will be offered ART as soon as possible.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1789">886 HIV-infected index cases and 903 HIV-uninfected partners</participants>
                <participants group_id="P2" count="1767">877 HIV-infected index cases and 890 HIV-uninfected partners</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1545"/>
                <participants group_id="P2" count="1541"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="244"/>
                <participants group_id="P2" count="226"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="49"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unable to adhere to visit schedule</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Relocated</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Were withdrawn by investigator</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Ended relationship w. index participant</title>
              <participants_list>
                <participants group_id="P1" count="117"/>
                <participants group_id="P2" count="106"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Early-ART</title>
          <description>Participants will begin ART in addition to receiving HIV primary care
Atazanavir: 300 mg taken orally once daily
Didanosine: 400 mg taken orally once daily
Efavirenz: 600 mg taken orally once daily
Emtricitabine/Tenofovir disoproxil fumarate: 200 mg emtricitabine/ 300 mg tenofovir disoproxil fumarate tablet taken orally once daily
Lamivudine: 300 mg taken orally once daily
Lopinavir/Ritonavir: 200 mg lopinavir/ 50 mg ritonavir tablet taken orally once daily
Nevirapine: 200 mg taken orally once daily for 14 days followed by 200 mg taken orally twice daily
Stavudine: Dosage depends on weight
Tenofovir disoproxil fumarate: 300 mg taken orally once daily
Zidovudine/Lamivudine: 150 mg lamivudine/ 300 mg zidovudine tablet taken orally twice daily
Note: Sites could also use locally supplied, FDA-approved drugs if they could be purchased with nonstudy funds. For participants with virologic failure, specified second-line treatment regimens were provided.</description>
        </group>
        <group group_id="B2">
          <title>Delayed-ART</title>
          <description>Participants will receive HIV primary care. When the CD4 count in these participants reaches 200 to 250 cells/mm3, drops below 200 cells/mm3, or develops an AIDS-defining illness, they will initiate ART.
(Same drug regimen as that described in the early-ART arm)
Note: Per LoA#5, on the Data and Safety and Monitoring Board (DSMB) recommendation, as of May 10, 2011, all HIV-infected participants in Arm 2 who have not already initiated ART will be offered ART as soon as possible.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1789"/>
            <count group_id="B2" value="1767"/>
            <count group_id="B3" value="3556"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>18-25 yr</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="300"/>
                    <measurement group_id="B2" value="335"/>
                    <measurement group_id="B3" value="635"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>26-40 yr</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1101"/>
                    <measurement group_id="B2" value="1079"/>
                    <measurement group_id="B3" value="2180"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;40 yr</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="388"/>
                    <measurement group_id="B2" value="353"/>
                    <measurement group_id="B3" value="741"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="877"/>
                    <measurement group_id="B2" value="860"/>
                    <measurement group_id="B3" value="1737"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="912"/>
                    <measurement group_id="B2" value="907"/>
                    <measurement group_id="B3" value="1819"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>North or South America</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="293"/>
                    <measurement group_id="B2" value="279"/>
                    <measurement group_id="B3" value="572"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="535"/>
                    <measurement group_id="B2" value="528"/>
                    <measurement group_id="B3" value="1063"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Africa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="961"/>
                    <measurement group_id="B2" value="960"/>
                    <measurement group_id="B3" value="1921"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Linked Partner HIV Infection Rates in Early-ART and Delayed-ART Arms</title>
        <description>incident HIV infections occurring in the partners (HIV-negative at enrollment) of randomized HIV-infected index (HIV-positive at enrollment) cases are assessed, by arm. Only acquisition from the index partner were included in the primary analysis, therefore, each endpoint was required to be confirmed (by genotyping) such that the viral envelop sequence in the index case matched that of the partner.</description>
        <time_frame>Throughout study</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Early-ART</title>
            <description>Participants will begin ART in addition to receiving HIV primary care
Atazanavir: 300 mg taken orally once daily
Didanosine: 400 mg taken orally once daily
Efavirenz: 600 mg taken orally once daily
Emtricitabine/Tenofovir disoproxil fumarate: 200 mg emtricitabine/ 300 mg tenofovir disoproxil fumarate tablet taken orally once daily
Lamivudine: 300 mg taken orally once daily
Lopinavir/Ritonavir: 200 mg lopinavir/ 50 mg ritonavir tablet taken orally once daily
Nevirapine: 200 mg taken orally once daily for 14 days followed by 200 mg taken orally twice daily
Stavudine: Dosage depends on weight
Tenofovir disoproxil fumarate: 300 mg taken orally once daily
Zidovudine/Lamivudine: 150 mg lamivudine/ 300 mg zidovudine tablet taken orally twice daily
Note: Sites could also use locally supplied, FDA-approved drugs if they could be purchased with nonstudy funds. For participants with virologic failure, specified second-line treatment regimens were provided.</description>
          </group>
          <group group_id="O2">
            <title>Delayed-ART</title>
            <description>Participants will receive HIV primary care. When the CD4 count in these participants reaches 200 to 250 cells/mm3, drops below 200 cells/mm3, or develops an AIDS-defining illness, they will initiate ART.
(Same drug regimen as that described in the early-ART arm)
Note: Per LoA#5, on the Data and Safety and Monitoring Board (DSMB) recommendation, as of May 10, 2011, all HIV-infected participants in Arm 2 who have not already initiated ART will be offered ART as soon as possible.</description>
          </group>
        </group_list>
        <measure>
          <title>Linked Partner HIV Infection Rates in Early-ART and Delayed-ART Arms</title>
          <description>incident HIV infections occurring in the partners (HIV-negative at enrollment) of randomized HIV-infected index (HIV-positive at enrollment) cases are assessed, by arm. Only acquisition from the index partner were included in the primary analysis, therefore, each endpoint was required to be confirmed (by genotyping) such that the viral envelop sequence in the index case matched that of the partner.</description>
          <units>event rate per 100 person-yr</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Person Years</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="903"/>
                <count group_id="O2" value="890"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Person Years</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4325"/>
                <count group_id="O2" value="4185"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.07" lower_limit="0.01" upper_limit="0.20"/>
                    <measurement group_id="O2" value="1.03" lower_limit="0.74" upper_limit="1.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.02</ci_lower_limit>
            <ci_upper_limit>0.22</ci_upper_limit>
            <estimate_desc>The hazard ratio estimate presented (0.07) is a comparison of the early-ART arm (numerator) to the delayed-ART arm (denominator), thus indicating a 93% lower risk of infection among all linked partner infections, during the entire study.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>All Partner HIV Infection Rates in Early-ART and Delayed-ART Arms</title>
        <description>All Incident HIV infections occurring in the partners (HIV-negative at enrollment) of randomized HIV-infected index (HIV-positive at enrollment) cases are assessed, by arm.</description>
        <time_frame>Throughout study</time_frame>
        <population>Population includes all partners (HIV-negative at enrollment) of randomized HIV-infected index (HIV-positive at enrollment) cases, by arm.</population>
        <group_list>
          <group group_id="O1">
            <title>Early-ART</title>
            <description>Participants will begin ART in addition to receiving HIV primary care
Atazanavir: 300 mg taken orally once daily
Didanosine: 400 mg taken orally once daily
Efavirenz: 600 mg taken orally once daily
Emtricitabine/Tenofovir disoproxil fumarate: 200 mg emtricitabine/ 300 mg tenofovir disoproxil fumarate tablet taken orally once daily
Lamivudine: 300 mg taken orally once daily
Lopinavir/Ritonavir: 200 mg lopinavir/ 50 mg ritonavir tablet taken orally once daily
Nevirapine: 200 mg taken orally once daily for 14 days followed by 200 mg taken orally twice daily
Stavudine: Dosage depends on weight
Tenofovir disoproxil fumarate: 300 mg taken orally once daily
Zidovudine/Lamivudine: 150 mg lamivudine/ 300 mg zidovudine tablet taken orally twice daily
Note: Sites could also use locally supplied, FDA-approved drugs if they could be purchased with nonstudy funds. For participants with virologic failure, specified second-line treatment regimens were provided.</description>
          </group>
          <group group_id="O2">
            <title>Delayed-ART</title>
            <description>Participants will receive HIV primary care. When the CD4 count in these participants reaches 200 to 250 cells/mm3, drops below 200 cells/mm3, or develops an AIDS-defining illness, they will initiate ART.
(Same drug regimen as that described in the early-ART arm)
Note: Per LoA#5, on the Data and Safety and Monitoring Board (DSMB) recommendation, as of May 10, 2011, all HIV-infected participants in Arm 2 who have not already initiated ART will be offered ART as soon as possible.</description>
          </group>
        </group_list>
        <measure>
          <title>All Partner HIV Infection Rates in Early-ART and Delayed-ART Arms</title>
          <description>All Incident HIV infections occurring in the partners (HIV-negative at enrollment) of randomized HIV-infected index (HIV-positive at enrollment) cases are assessed, by arm.</description>
          <population>Population includes all partners (HIV-negative at enrollment) of randomized HIV-infected index (HIV-positive at enrollment) cases, by arm.</population>
          <units>event rate per 100 person-yr</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="903"/>
                <count group_id="O2" value="890"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.44" lower_limit="0.26" upper_limit="0.69"/>
                    <measurement group_id="O2" value="1.41" lower_limit="1.07" upper_limit="1.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.31</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.19</ci_lower_limit>
            <ci_upper_limit>0.53</ci_upper_limit>
            <estimate_desc>The hazard ratio estimate presented (0.31) is a comparison of the early-ART arm (numerator) to the delayed-ART arm (denominator), thus indicating a 69% lower risk of infection among all partner infections, during the entire study.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Only index participants were monitored for adverse events since they (and not partners) were receiving treatment drugs.</desc>
      <group_list>
        <group group_id="E1">
          <title>Early-ART</title>
          <description>Participants will begin ART in addition to receiving HIV primary care
Atazanavir: 300 mg taken orally once daily
Didanosine: 400 mg taken orally once daily
Efavirenz: 600 mg taken orally once daily
Emtricitabine/Tenofovir disoproxil fumarate: 200 mg emtricitabine/ 300 mg tenofovir disoproxil fumarate tablet taken orally once daily
Lamivudine: 300 mg taken orally once daily
Lopinavir/Ritonavir: 200 mg lopinavir/ 50 mg ritonavir tablet taken orally once daily
Nevirapine: 200 mg taken orally once daily for 14 days followed by 200 mg taken orally twice daily
Stavudine: Dosage depends on weight
Tenofovir disoproxil fumarate: 300 mg taken orally once daily
Zidovudine/Lamivudine: 150 mg lamivudine/ 300 mg zidovudine tablet taken orally twice daily
Note: Sites could also use locally supplied, FDA-approved drugs if they could be purchased with nonstudy funds. For participants with virologic failure, specified second-line treatment regimens were provided.</description>
        </group>
        <group group_id="E2">
          <title>Delayed-ART</title>
          <description>Participants will receive HIV primary care. When the CD4 count in these participants reaches 200 to 250 cells/mm3, drops below 200 cells/mm3, or develops an AIDS-defining illness, they will initiate ART.
(Same drug regimen as that described in the early-ART arm)
Note: Per LoA#5, on the Data and Safety and Monitoring Board (DSMB) recommendation, as of May 10, 2011, all HIV-infected participants in Arm 2 who have not already initiated ART will be offered ART as soon as possible.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA Body System</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="526" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="522" subjects_at_risk="877"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Anaemia of pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Haemolytic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Lymphadenitis</sub_title>
                <description>General disorders as well as administration site conditions</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="62" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="66" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="877"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Cor pulmonale</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Left ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Congenital anomaly in offspring</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Hydrocele</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="877"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retinal artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Ulcerative keratitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Acute abdomen</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Anal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Diarrhoea haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Food poisoning</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Mouth ulceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Peptic ulcer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="877"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Hyperthermia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Peripheral swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="877"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Cirrhosis alcoholic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Drug-induced liver injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Hepatic cirrhosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Hepatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Hepatitis alcoholic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Hepatotoxicity</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Liver disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="877"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="877"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abortion infected</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Abscess bacterial</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Appendicitis perforated</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Bacterial pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Bacterial sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Cerebral malaria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Dengue fever</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Diarrhoea infectious</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Disseminated tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Dysentery</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Enteritis infectious</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Extrapulmonary tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Furuncle</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Gastrointestinal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>H1N1 influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Herpes zoster oticus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Joint abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Leptospirosis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Liver abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Lymph node tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Malaria</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Measles</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Meningitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Meningitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Meningitis cryptococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Meningitis tuberculous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Meningococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Meningoencephalitis herpetic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Muscle abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Nasal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Osteomyelitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Pelvic abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Pelvic inflammatory disease</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Pharyngitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Plasmodium falciparum infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Plasmodium malariae infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Pneumocystis jirovecii pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Pneumonia viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Post procedural infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Progressive multifocal leukoencephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Pulmonary sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Secondary syphilis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Tonsillitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Tracheobronchitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Tuberculosis gastrointestinal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Tuberculous pleurisy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Tubo-ovarian abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Typhoid fever</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Vulval abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Abdominal injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Alcohol poisoning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Chemical poisoning</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Dislocation of vertebra</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Exposure to toxic agent</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Forearm fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Gun shot wound</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Hair injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Poisoning</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Post procedural diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Procedural dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Procedural vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Skin abrasion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Skull fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Snake bite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Soft tissue injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Traumatic haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="877"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Blood albumin decreased</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Blood bicarbonate decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="68" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Blood cholesterol increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Blood phosphorus decreased</sub_title>
                <counts group_id="E1" subjects_affected="73" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="86" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Blood phosphorus increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Blood potassium decreased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Blood potassium increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Blood sodium decreased</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Blood sodium increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Blood triglycerides increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Low density lipoprotein increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="64" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="80" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal loss of weight</sub_title>
                <counts group_id="E1" subjects_affected="75" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Dyslipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Hypernatraemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Hyperphosphataemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridaemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Lactic acidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Metabolic acidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Obesity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="877"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Hypercreatinaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Plantar fasciitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Systemic lupus erythematosus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Trigger finger</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Adenocarcinoma gastric</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>B-cell lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Benign hydatidiform mole</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Cervix carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Choriocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Colon adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Colorectal adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Hepatocellular carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Hodgkin's disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Non-Hodgkin's lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Phyllodes tumour</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Rectal adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="877"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Central nervous system lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Cerebral atrophy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Diplegia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Dizziness postural</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Febrile convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Haemorrhagic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Intracranial venous sinus thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Paraplegia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Polyneuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Tonic convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>VIIth nerve paralysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="877"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Abortion complete</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Abortion incomplete</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Abortion missed</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Abortion spontaneous incomplete</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Abortion threatened</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Cephalo-pelvic disproportion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Ectopic pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>False labour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Foetal death</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Gestational hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Haemorrhage in pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Placenta praevia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Pre-eclampsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Premature baby</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Premature labour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Premature rupture of membranes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Ruptured ectopic pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Stillbirth</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Acute psychosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Acute stress disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Aggression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Bipolar disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Brief psychotic disorder, with postpartum onset</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Depressed mood</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Drug abuse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Hallucination</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Homicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Intentional self-injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Mental disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Violence-related symptom</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="877"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Chronic kidney disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Nephrotic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Urogenital fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Cervical dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Dysfunctional uterine bleeding</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Erectile dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Gynaecomastia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Menstrual disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Pelvic pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Postmenopausal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Uterine haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Vulvovaginal swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Pharyngeal mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Cutaneous lupus erythematosus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Decubitus ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Lipodystrophy acquired</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Rash generalised</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Victim of homicide</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Diabetic vascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Systolic hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Thromboangiitis obliterans</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis superficial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="877"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="886"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="877"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>All study abstracts and publications are subject to HPTN Publication and Public Information Policies and Clinical Trial Agreements between NIAID (DAIDS) and company collaborators. The publication or other disclosure can be delayed for up to thirty additional business days for manuscripts and five business days for abstracts, to preserve U.S. or foreign patent or other intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Deborah Donnell</name_or_title>
      <organization>Fred Hutchinson Cancer Research Center</organization>
      <phone>2066675661</phone>
      <email>deborah@scharp.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

